Happy Chinese New Year ! ! !
As the Spring Festival of the Year of the Snake in 2025 approaches, I wish all our great partners a happy New Year! All the best!
Pharmacology and Synthesis of Ruxolitinib
Pharmacology and Synthesis of Ruxolitinib Pharmacology Ruxolitinib is a potent inhibitor of Janus-associated kinases (JAK) 1 and 2, which play crucial roles in the signaling pathways for various cytokines and growth factors involved in hematopoiesis and immune function. The dysregulation of JAK-STAT ...
FarmaSino is Ready for CPHI China 2024!
CPHI & PMEC China is Asia’s leading pharmaceutical show for trading, knowledge sharing and networking. It spans all industry sectors along the pharmaceutical supply chain and is your one-stop platform to grow business in the 2nd largest pharma market in the world. CPHI & PMEC China 2024, with the co...
Apixaban - a novel oral anticoagulant
Apixaban is a novel oral anticoagulant. It is possible to directly, reversibly, and highly selectively block the active site of factor Xa, blocking the conversion of prothrombin to thrombin, and thereby preventing thrombosis. As compared with rivaroxaban, apixaban also prevents thrombosis by ...
Semaglutide reduces heart failure–related symptoms and physical limitations
On 6 Aprile 2024, Novo Nordisk published the result of STEP HFpEF DM on the New England Journal of Medicine. The results demonstrated that among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure...
Visit FarmaSino at API China 2024 Shanghai
API China focuses on improving the overall level of production, research and development of pharmaceutical raw materials, intermediates and pharmaceutical excipient in China, representing new products and technologies in China's pharmaceutical industry. API China has become a brand event that brings ...
GLP-1: A Multifunctional Target
As an important class of hypoglycemic and weight loss drugs, GLP-1 drugs have attracted much attention and made significant development in recent years. Since GLP-1 drugs were found to have hypoglycemic effects, GLP-1 targets have been firmly in the hot track, especially after the approval of ...
Top 30 Anti-tumor Drugs in 2023 (In billion dollars)
Top 30 Anti-tumor Drugs in 2023 (In billion dollars) No. Drug name Company Main indications Sales Growth rate 1 Keytruda (pembrolizumab) MSD Melanoma, NSCLC, Bladder cancer, HNC 25.01 19.5% 2 Opdivo (nivolumab) BMS/ONO Melanoma, NSCLC, HNC 10.04 9.0% 3 Darzalex (daratumumab) Johnson & Johnson ...
FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
On 8 March, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. The FDA decision is based on the results ...
SNAC: A Stepping Stone to Oral Semaglutide
Salcaprozate sodium (SNAC) is the sodium salt form of salcaprozate. It is used in the treatment of gastrointestinal disorders, especially gastrointestinal disorders caused by the malabsorption of dicarbonate-phosphate compounds. SNAC can also promote the absorption of drugs in gastrointestinal ...
Semaglutide APIs and Related Intermediates in Different Specifications
Semaglutide is an anti-diabetic drug which is used to treat type 2 diabetes and manage chronic weight. Semaglutide is a glucagon-like peptide-1(GLP-1) receptor agonist with 94% sequence homology with human GLP-1. It increases the production of insulin, which can lower the blood glucose level. ...
Maghreb Pharma Expo 2024
Farmasino adheres to the localization development of Algeria. It provides a one-stop solution for the local biopharmaceutical industry, from raw materials to registration documents, from production processes to pharmaceutical machinery. In 2023, its cumulative exports exceeded 20 million US dollars. ...
Happy Chinese New Year ! ! !
As the Spring Festival of the Year of the Snake in 2025 approaches, I wish all our great partners a happy New Year! All the best!
Pharmacology and Synthesis of Ruxolitinib
Pharmacology and Synthesis of Ruxolitinib Pharmacology Ruxolitinib is a potent inhibitor of Janus-associated kinases (JAK) 1 and 2, which play crucial roles in the signaling pathways for various cytokines and growth factors involved in hematopoiesis and immune function. The dysregulation of JAK-STAT ...
FarmaSino is Ready for CPHI China 2024!
CPHI & PMEC China is Asia’s leading pharmaceutical show for trading, knowledge sharing and networking. It spans all industry sectors along the pharmaceutical supply chain and is your one-stop platform to grow business in the 2nd largest pharma market in the world. CPHI & PMEC China 2024, with the co...
Apixaban - a novel oral anticoagulant
Apixaban is a novel oral anticoagulant. It is possible to directly, reversibly, and highly selectively block the active site of factor Xa, blocking the conversion of prothrombin to thrombin, and thereby preventing thrombosis. As compared with rivaroxaban, apixaban also prevents thrombosis by ...
Semaglutide reduces heart failure–related symptoms and physical limitations
On 6 Aprile 2024, Novo Nordisk published the result of STEP HFpEF DM on the New England Journal of Medicine. The results demonstrated that among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure...
Visit FarmaSino at API China 2024 Shanghai
API China focuses on improving the overall level of production, research and development of pharmaceutical raw materials, intermediates and pharmaceutical excipient in China, representing new products and technologies in China's pharmaceutical industry. API China has become a brand event that brings ...
GLP-1: A Multifunctional Target
As an important class of hypoglycemic and weight loss drugs, GLP-1 drugs have attracted much attention and made significant development in recent years. Since GLP-1 drugs were found to have hypoglycemic effects, GLP-1 targets have been firmly in the hot track, especially after the approval of ...
Top 30 Anti-tumor Drugs in 2023 (In billion dollars)
Top 30 Anti-tumor Drugs in 2023 (In billion dollars) No. Drug name Company Main indications Sales Growth rate 1 Keytruda (pembrolizumab) MSD Melanoma, NSCLC, Bladder cancer, HNC 25.01 19.5% 2 Opdivo (nivolumab) BMS/ONO Melanoma, NSCLC, HNC 10.04 9.0% 3 Darzalex (daratumumab) Johnson & Johnson ...
FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
On 8 March, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. The FDA decision is based on the results ...
SNAC: A Stepping Stone to Oral Semaglutide
Salcaprozate sodium (SNAC) is the sodium salt form of salcaprozate. It is used in the treatment of gastrointestinal disorders, especially gastrointestinal disorders caused by the malabsorption of dicarbonate-phosphate compounds. SNAC can also promote the absorption of drugs in gastrointestinal ...
Semaglutide APIs and Related Intermediates in Different Specifications
Semaglutide is an anti-diabetic drug which is used to treat type 2 diabetes and manage chronic weight. Semaglutide is a glucagon-like peptide-1(GLP-1) receptor agonist with 94% sequence homology with human GLP-1. It increases the production of insulin, which can lower the blood glucose level. ...
Maghreb Pharma Expo 2024
Farmasino adheres to the localization development of Algeria. It provides a one-stop solution for the local biopharmaceutical industry, from raw materials to registration documents, from production processes to pharmaceutical machinery. In 2023, its cumulative exports exceeded 20 million US dollars. ...
